[{"notes_id":"1_1164","category":"1","subcategory":"1","title":"Heparin","body":"There are two main types of heparin - unfractionated, 'standard' heparin or low molecular weight heparin (LMWH). Heparins generally act by activating antithrombin III. Unfractionated heparin forms a complex which inhibits thrombin, factors Xa, IXa,  XIa and XIIa. LMWH however only increases the action of antithrombin III on factor Xa<br \/><br \/>Adverse effects of heparins include:<br \/><ul><li>bleeding<\/li><li><span class=\"concept\" data-cid=\"7506\">thrombocytopenia<\/span> - see below<\/li><li><span class=\"concept\" data-cid=\"7508\">osteoporosis<\/span> and an <span class=\"concept\" data-cid=\"7510\">increased risk of fractures<\/span><\/li><li><span class=\"concept\" data-cid=\"7507\">hyperkalaemia<\/span> - this is thought to be caused by inhibition of aldosterone secretion<\/li><\/ul><br \/>The table below shows the differences between standard heparin and LMWH:<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><\/th><th><b>Standard heparin<\/b><\/th><th><b>Low molecular weight heparin (LMWH)<\/b><\/th><\/tr><\/thead><tbody><tr><td><b>Administration<\/b><\/td><td>Intravenous<\/td><td>Subcutaneous<\/td><\/tr><tr><td><b>Duration of action<\/b><\/td><td>Short<\/td><td>Long<\/td><\/tr><tr><td><b>Mechanism of action<\/b><\/td><td><span class=\"concept\" data-cid=\"7509\">Activates antithrombin III. Forms a complex that inhibits thrombin, factors Xa, IXa,  Xia and XIIa<\/span><\/td><td><span class=\"concept\" data-cid=\"7511\">Activates antithrombin III. Forms a complex that inhibits factor Xa<\/span><\/td><\/tr><tr><td><b>Side-effects<\/b><\/td><td>Bleeding<br \/>Heparin-induced thrombocytopaenia (HIT)<br \/>Osteoporosis<\/td><td>Bleeding<br \/><br \/>Lower risk of HIT and osteoporosis with LMWH<\/td><\/tr><tr><td><b>Monitoring<\/b><\/td><td>Activated partial thromboplastin time (APTT)<\/td><td>Anti-Factor Xa (although routine monitoring is not required)<\/td><\/tr><tr><td><b>Notes<\/b><\/td><td>Useful in situations where there is a high risk of bleeding as anticoagulation can be terminated rapidly. Also useful in <span class=\"concept\" data-cid=\"9275\">renal failure<\/span><\/td><td>Now standard in the management of venous thromboembolism treatment and prophylaxis and acute coronary syndromes<\/td><\/tr><\/tbody><\/table><\/div><br \/><h5 class='notes-heading'>Heparin-induced thrombocytopaenia (HIT)<\/h5><br \/>Immune-mediated adverse reaction to heparin causing thrombocytopenia and <span class=\"concept\" data-cid=\"5696\">paradoxical thrombosis<\/span>.<br \/><br \/>Pathophysiology<br \/><ul><li><span class=\"concept\" data-cid=\"189\">IgG antibodies form against platelet factor 4 (PF4)\u2013heparin complexes<\/span><\/li><li>Antibody binding activates platelets by by cross-linking Fc&gamma;IIA receptors \u2192 thrombosis and platelet consumption.<\/li><\/ul><br \/>Types<br \/><ul><li>Type I: mild, non-immune, early (within 1\u20132 days), transient, not clinically significant.  <\/li><li>Type II: immune-mediated, typically 5\u201314 days after exposure, associated with thrombosis.<\/li><\/ul><br \/>Clinical features  <br \/><ul><li>Platelet count fall >50% from baseline.  <\/li><li>Occurs 5\u201314 days after starting heparin (earlier if previously exposed).  <\/li><li>Venous and arterial thromboses (DVT, PE, limb ischaemia, MI, stroke).  <\/li><li>Skin necrosis at injection sites.<\/li><\/ul><br \/>Investigations<br \/><ul><li><span class=\"concept\" data-cid=\"12555\">4T score to assess probability<\/span>.  <\/li><li>Confirm with HIT antibody (anti-PF4 ELISA) \u00b1 functional assays (serotonin release assay).<\/li><\/ul><br \/>Management<br \/><ul><li>Stop all heparin immediately (including flushes).  <\/li><li>Avoid LMWH as cross-reactivity occurs.  <\/li><li>Start alternative anticoagulant. Options include:<ul><li>Direct thrombin inhibitors: e.g. <span class=\"concept\" data-cid=\"11199\">argatroban<\/span>, bivalirudin (particularly useful if renal impairment or rapid reversal needed)<\/li><li>Danaparoid<\/li><li>Direct oral anticoagulants (DOACs)<\/li><\/ul><\/li><li>Do not transfuse platelets unless life-threatening bleeding.  <\/li><li>Document allergy and avoid future heparin exposure.<\/li><\/ul><br \/><br \/><h5 class='notes-heading'>Heparin overdose<\/h5><br \/>Heparin overdose may be reversed by <span class=\"concept\" data-cid=\"7512\">protamine sulphate<\/span>, although this only partially reverses the effect of LMWH.","notes_hash":"c3bf2facf45d9713e44c340c8fea81d0","knowledge_graph_node_id_link":10889,"links":"<table style='width:100%'><tr><td>BNF<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_130\" data-linkid=\"130\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_130\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">8<\/span><button type=\"button\" style=\"\" id=\"link_dislike_130\" data-linkid=\"130\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_130\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">6<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/bnf.nice.org.uk\/drug\/heparin-unfractionated.html\">Heparin<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>British Society for Haematology<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_131\" data-linkid=\"131\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_131\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">10<\/span><button type=\"button\" style=\"\" id=\"link_dislike_131\" data-linkid=\"131\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_131\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">5<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/bjh.12059\">2012 HIT guidelines<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/QdEKY2xzB_U\" data-description=\"Heparin-induced thrombocytopenia\" data-upvotes=\"2\" data-downvotes=\"1\" data-media=\"903\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/QdEKY2xzB_U\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/QdEKY2xzB_U\" data-description=\"Heparin-induced thrombocytopenia\" data-upvotes=\"2\" data-downvotes=\"1\" data-media=\"903\">Heparin-induced thrombocytopenia<\/a><\/td><\/tr><tr><td><span ><small>Osmosis - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1569\" data-mediaid=\"1569\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1569\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">2<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1569\" data-mediaid=\"1569\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1569\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"7506":{"concept_text":"Heparin may cause thrombocytopaenia","concept_percentile":"19"},"7507":{"concept_text":"Heparin may cause hyperkalaemia","concept_percentile":"12"},"7508":{"concept_text":"Heparin may cause osteoporosis","concept_percentile":"11"},"7509":{"concept_text":"Unfractionated heparin - activates antithrombin III. Forms a complex that inhibits thrombin, factors Xa, Ixa,  Xia and XIIa","concept_percentile":"16"},"7511":{"concept_text":"Low-molecular weight heparin activates antithrombin III. Forms a complex that inhibits factor Xa","concept_percentile":"20"}},"category_name":"Cardiovascular","subcategory_name":"Cardiology","comment_count":2},"",[]]